We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 77.51%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VXRT
101
DELISTED
Vaxart
VXRT
$1.72M 0.02%
75,495
-2,976
-4% -$73.1K
BDSI
102
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.67M 0.01%
210,021
-45,845
-18% -$394K
MDWD icon
103
MediWound
MDWD
$171M
$1.59M 0.01%
32,143
– –
ALNY icon
104
Alnylam Pharmaceuticals
ALNY
$31.6B
$1.36M 0.01%
11,340
– –
TENX icon
105
Tenax Therapeutics
TENX
$65.5M
$1.31M 0.01%
+11
New +$1.25M
ALDX icon
106
Aldeyra Therapeutics
ALDX
$91.7M
$1.1M 0.01%
142,000
– –
NBSE
107
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$930K 0.01%
926
– –
XLRN
108
DELISTED
Acceleron Pharma
XLRN
$910K 0.01%
28,765
– –
QURE icon
109
uniQure
QURE
$3.36B
$810K 0.01%
30,000
– –
FMI
110
DELISTED
Foundation Medicine, Inc.
FMI
$707K 0.01%
20,892
-103,363
-83% -$4.16M
AKAO
111
DELISTED
Achaogen Inc
AKAO
$603K 0.01%
100,000
– –
FPRX
112
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$478K ﹤0.01%
19,247
– –
CCXI
113
DELISTED
ChemoCentryx, Inc.
CCXI
$404K ﹤0.01%
49,064
– –
APTO
114
DELISTED
Aptose Biosciences, Inc.
APTO
$170K ﹤0.01%
74
– –
BTX.WS
115
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$23K ﹤0.01%
20,084
– –
LPCN icon
116
Lipocine
LPCN
$17.2M
– –
-28,775
Closed -$3.38M
MDGL icon
117
Madrigal Pharmaceuticals
MDGL
$11.9B
– –
-13,973
Closed -$949K
OSUR icon
118
OraSure Technologies
OSUR
$268M
– –
-229,397
Closed -$1.5M
RIGL icon
119
Rigel Pharmaceuticals
RIGL
$857M
– –
-35,719
Closed -$1.27M
EIGR
120
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-815
Closed -$6.95M
INFI
121
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-305,037
Closed -$4.26M
ALBO
122
DELISTED
Albireo Pharma Inc
ALBO
– –
-1,006
Closed -$36K
AEGR
123
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-14,300
Closed -$374K
GEVA
124
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-11,660,432
Closed -$1.14B
PCYC
125
DELISTED
PHARMACYCLICS INC
PCYC
– –
-9,039,652
Closed -$2.31B
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2015 Portfolio in Review

As of Q2 2015, Julian Baker held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Julian Baker withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 46% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Julian Baker's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Julian Baker added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Julian Baker's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Julian Baker fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Julian Baker's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Julian Baker opened 10 new positions and closed 12 in Q2 2015.
  • Julian Baker's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.